Milestone Scientific Expands Medical Indications for CompuFlo® Epidural Instrument and Begins Selling Disposable Products to Leading Veterinary and Academic Institution

ROSELAND, NJ, May 27, 2022 (GLOBE NEWSWIRE) — Milestone Scientific, Inc. (NYSE: MLSS), a leading developer of computerized drug delivery devices that enable precise and painless injections, today announced that it has begun selling its CompuFlo® epidural disposable instruments in a leading veterinary and academic institution following successful research study and evaluation. The veterinary institution initially began using the CompuFlo Epidural instrument for maxillary nerve block procedures in horses with plans to expand into epidural procedures.

The CompuFlo Epidural instrument has been evaluated in multiple studies in veterinary medicine. A published study in June 2020, which focused on maxillary nerve block in horses, concluded that the use of the CompuFlo Epidural instrument would not only serve as a valuable educational tool, but would also increase the success rate for less experienced equine practitioners. The study further noted that the CompuFlo/DPS® The technology provided beneficial guidance to the operator during needle insertion at the intended target location, increasing the overall success rate compared to using only anatomical surface landmarks for guidance.

Dr. Bernd Driessen, an equine anesthesiologist who has been involved in previous clinical studies of the instrument, commented, “I am delighted to see the commercial adoption of the CompuFlo Epidural instrument in clinical practice, as well as in the classroom. to educate the next generation of veterinarians. . The CompuFlo Epidural instrument can provide other veterinarians and students with greater accuracy through real-time verification of needle location when performing a maxillary nerve block.

Arjan HaverhalsCEO of Scientific milestone, said, “The team at this institution is continually leading the way in advances in veterinary medicine, and we are honored to provide them with our proven technology. Milestone is continually evaluating additional channels to commercialize our technology, including new medical indications. Veterinary medicine is just one example of another market that will benefit from our CompluFlo Epidural instrument. We believe that the extensive prior studies, covering epidural, peripheral nerve block, intra-articular and veterinary use cases, reinforce the increased safety, improved outcomes, economic benefits and broad market potential of our instrument.

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology-driven medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise and efficient and to increase patient comfort and safety. Their exclusive DPS dynamic pressure sensing technology® instruments is the platform to advance the development of next-generation devices, regulating flow and monitoring pressure from the needle tip, through subcutaneous drug delivery platform extensions , including local anesthetic. To find out more, see the MLSS Brand Video or visit milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments regarding future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict with precision and many of which go beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve anticipated revenue growth, changes in our operating expenses, decisions adverse patent, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation Milestone’s annual report for the year ended December 31, 2020. The forward-looking statements contained in this press release are based on management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to publicly revise or update any forward-looking statements for any reason.

Contact:
David Waldman or Natalia Rudman
Crescendo Communications, LLC
E-mail: [email protected]
Tel: 212-671-1020


main logo

About Michael Bill

Check Also

Orphan Indication Treatment Market Growth Prospects: 2022, Regional Demand, Qualitative Analysis and Dynamic Innovations | Bristol-Myers Squibb, Roche, Novartis

The latest report published by SMI provides a comprehensive assessment of “Orphan Indications Treatment Market …